Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
77931.050.1182%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

LB Pharmaceuticals Inc

LBRXNASDAQ
Trade with Public
Trade with Public
$47.73
-0.16-0.33%
At close: Aug 28, 5:00 PM EST
$47.73
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

LB Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for LB Pharmaceuticals (LBRX).

Price Target Range — 4 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$50Upside to Avg. PT+3.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 24, 2026HC Wainwright & Co.Raghuram SelvarajuPT RaiseBuy$45→$60
Aug 12, 2026BMO CapitalMalcolm HoffmanPT RaiseOutperform$46→$54
More with Benzinga EdgeGet Access

Analyst Ratings News

Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60

HC Wainwright & Co. analyst Raghuram Selvaraju maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $45 to $60.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54

BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and maintains $45 price target.
Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46

BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $46.
Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $45.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved